November 2023

Traitement au bimékizumab chez les patients atteints de spondylarthrite axiale active: efficacité et innocuité à 52 semaines des études randomisées et parallèles de phase 3 BE MOBILE 1 et BE MOBILE 2

Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803

Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.

Keywords:

October 2023

Otilimab anti-GM-CSF versus Sarilumab ou placebo chez des patients atteints de polyarthrite rhumatoïde et avec une réponse inadéquate aux thérapies ciblées : Un essai randomisé de phase III (contRAst 3)

Ann Rheum Dis. 2023;82(12):1527–1537 doi 10.1136/ard-2023-224449

The ContRAst 3 study investigated otilimab, in RA patients with inadequate responses to multiple treatments. Otilimab did not significantly improve ACR20 versus placebo at Weeks 12 or 24. In addition, there we no significant improvements in secondary endpoints, including disease activity, disability, and pain.

Keywords:

Anti-GM-CSF Otilimab versus Tofacitinib ou placebo chez des patients atteints de polyarthrite rhumatoïde active et présentant une réponse inadéquate aux DMARD conventionnels ou biologiques : Deux essais randomisés de phase 3 (contRAst 1 et contRAst 2)

Ann Rheum Dis 2023;0:1–11 doi 10.1136/ard-2023-224482

Fleischmann, et al investigated the safety and efficacy of otilimab versus tofacitinib and placebo in RA patients treated with MTX (contRAst 1) or csDMARDs (contRAst 2). They found that while otilimab achieved the primary endpoint of ACR20 versus placebo in Week 12, it did not demonstrate non-inferiority to tofacitinib.

Keywords:

July 2023

Efficacité comparative du baricitinib en première intention chez les patients atteints de polyarthrite rhumatoïde dans l'ensemble de données australien OPAL

ACR Open Rheumatol. 2023;5(7):345-353 doi 10.1002/acr2.11577

Cicirello, et al. present results showing that baricitinib is comparable in treatment persistence with TNF inhibitors. However, treatment persistence up to 24 months was significantly longer for baricitinib, but the effect size of one month is not clinically meaningful.

Keywords:

February 2023

Efficacité et sécurité du bimekizumab dans la spondylarthrite axiale : Résultats de deux essais contrôlés randomisés de phase 3 menés en parallèle

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

January 2023

Innocuité et efficacité du bimekizumab chez les patients atteints de spondylarthrite ankylosante active : Résultats à trois ans d'un essai contrôlé randomisé de phase IIb et de son étude de prolongation ouverte

Arthritis Rheumatol. 2022;74:1943–58

In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.

Keywords:

October 2022

Efficacité et innocuité de l'Ixekizumab versus Adalimumab chez des patients naïfs de produits biologiques atteints de rhumatisme psoriasique actif et de psoriasis modéré à sévère: Résultats de l'étude randomisée SPIRIT-H2H à 52 semaines

Dermatol Pract Concept. 2022 doi: 10.5826/dpc.1202a104

Ixekizumab (IXE)-treated patients achieved significantly greater simultaneous PASI100 and ACR50 responses through W52 versus adalimumab (ADA)-treated, confirming IXE as an efficacious and safe treatment. This study investigated the efficacy and safety of IXE and ADA in the subgroup of patients with PsA and moderate-to-severe PsO through W52.

Keywords:

August 2022

Sécurité et efficacité du bimekizumab chez les patients atteints de spondylarthrite ankylosante active : résultats à 3 ans d'un essai contrôlé randomisé de phase 2b et de son étude de prolongation en ouvert

Arthritis Rheumatol 2022 doi: 10.1002/art.42282

Bimekizumab is associated with sustained, long-term efficacy in r-axSpA patinets across three years of treatment. In coming to this conclusion, investigators sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in active r-axSpA.

Keywords:

September 2021

Real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia

Clin Rheumatol. 2021. Epub ahead of print doi: 10.1007/s10067-021-05853-x

Real-world evidence suggests that monotherapy and combination therapy tofacitinib is an effective intervention in RA with persistence and effectiveness comparable to bDMARDs. Despite recommendations from EULAR that bDMARDs and tsDMARDs be used in combination with csDMARDs for the treatment of RA, it is estimated that up to a third of patients take their medication as monotherapy.This post hoc analysis of data from the Australian OPAL study by Bird, et al. aimed to describe the real-world effecti...

Keywords:

April 2021

Analyse Comparative des Inhibiteurs de BTK et des Mécanismes à l'Origine des Effets Indésirables

Front. Cell Dev. Biol. 9:630942 DOI: 10.3389/fcell.2021.630942

Understanding of the B-cell receptor signalling pathway led to the identification of a suitable drug target to addresses autoimmunity and inflammation in areas such as MS, RA, pemphigus and SLE. There are currently 22 BTKis in various stages of clinical development. However, AEs such as cardiovascular and bleeding side effects, as well as rash, diarrhoea and infections have been associated with the inhibition of other kinases with a BTKi-binding cysteine in their catalytic domain.Based on clinic...

Keywords: